How did OCUL's revenue and expenses trend in Q4 2024?
4/14/2025 10:29am
Aime
Ocular Therapeutix (OCUL) experienced a significant decline in net income in Q4 2024, with a net loss of $48.39 million, despite a total revenue of $17.08 million. The R&D expenses were notably high at $40.99 million for the quarter1.
OCUL R&D Expenses, Total Revenue...
Source:
1.
OCUL Revenue (Q4 2024), R&D Expenses (Q4 2024), SG&A Expenses (Q4 2024), Net Income (Q4 2024)
more
less
Explore
Screener
Best looking stocks that are MACD Golden Cross
Analysis
What is the trend of APOG's stock price?
Learn
What is a smart contract and give examples
Wiki
For diabetes, what foods or drink are good to consume?